Among these, only two were approved by the U.S. Food and Drug Administration (FDA); Niclosamide was approved by the FDA to treat tapeworm infection in 1982 [35], and Tipifarnib recently received a breakthrough therapy designation by the FDA for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) [36]. The gene discussed is HRAS; the disease is Cestode infectious disease.